US5013497A
(en)
*
|
1988-03-03 |
1991-05-07 |
Micro-Pak, Inc. |
Method and apparatus for producing lipid vesicles
|
US5405497A
(en)
*
|
1990-08-28 |
1995-04-11 |
Kamyr, Inc. |
Method of chemically reacting a liquid with a gas in a vortex
|
GB9320455D0
(en)
*
|
1993-10-05 |
1993-11-24 |
Atomic Energy Authority Uk |
Vortex mixer
|
US6310197B1
(en)
|
1997-11-12 |
2001-10-30 |
The Brigham And Women's Hospital, Inc. |
Translation enhancer element of the human amyloid precursor protein gene
|
EP1259602A1
(en)
|
2000-01-28 |
2002-11-27 |
The Scripps Research Institute |
Methods of identifying synthetic transcriptional and translational regulatory elements, and compositions relating to same
|
US7468275B2
(en)
|
2000-01-28 |
2008-12-23 |
The Scripps Research Institute |
Synthetic internal ribosome entry sites and methods of identifying same
|
WO2001089675A2
(en)
*
|
2000-05-24 |
2001-11-29 |
Micronics, Inc. |
Jet vortex mixer
|
EP2305699B1
(en)
|
2001-06-05 |
2014-08-13 |
CureVac GmbH |
Stabilised mRNA with increased G/C content which is optimised for translation in its coded areas for the vaccination against sleeping sickness, leishmaniosis and toxoplasmosis
|
DE10162480A1
(en)
|
2001-12-19 |
2003-08-07 |
Ingmar Hoerr |
The application of mRNA for use as a therapeutic agent against tumor diseases
|
DE10229872A1
(en)
|
2002-07-03 |
2004-01-29 |
Curevac Gmbh |
Immune stimulation through chemically modified RNA
|
DE10335833A1
(en)
|
2003-08-05 |
2005-03-03 |
Curevac Gmbh |
Transfection of blood cells with mRNA for immune stimulation and gene therapy
|
DE102004042546A1
(en)
|
2004-09-02 |
2006-03-09 |
Curevac Gmbh |
Combination therapy for immune stimulation
|
DE102005023170A1
(en)
|
2005-05-19 |
2006-11-23 |
Curevac Gmbh |
Optimized formulation for mRNA
|
AU2006283077B2
(en)
|
2005-08-24 |
2012-06-28 |
The Scripps Research Institute |
Translation Enhancer-Element dependent vector systems
|
DE102006007433A1
(en)
|
2006-02-17 |
2007-08-23 |
Curevac Gmbh |
Immunostimulant adjuvant useful in vaccines against cancer or infectious diseases comprises a lipid-modified nucleic acid
|
EP2049665A2
(en)
|
2006-07-28 |
2009-04-22 |
Applera Corporation |
Dinucleotide mrna cap analogs
|
EP2046954A2
(en)
|
2006-07-31 |
2009-04-15 |
Curevac GmbH |
NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
|
JP5030520B2
(en)
|
2006-09-29 |
2012-09-19 |
富士フイルム株式会社 |
Fluid mixing method and microdevice
|
DE102006051516A1
(en)
|
2006-10-31 |
2008-05-08 |
Curevac Gmbh |
(Base) modified RNA to increase the expression of a protein
|
DE102006061015A1
(en)
|
2006-12-22 |
2008-06-26 |
Curevac Gmbh |
Process for the purification of RNA on a preparative scale by HPLC
|
DE102007001370A1
(en)
|
2007-01-09 |
2008-07-10 |
Curevac Gmbh |
RNA-encoded antibodies
|
WO2008127688A1
(en)
|
2007-04-13 |
2008-10-23 |
Hart Communication Foundation |
Synchronizing timeslots in a wireless communication protocol
|
WO2009030254A1
(en)
|
2007-09-04 |
2009-03-12 |
Curevac Gmbh |
Complexes of rna and cationic peptides for transfection and for immunostimulation
|
CA2904904A1
(en)
|
2007-12-11 |
2009-06-18 |
The Scripps Research Institute |
Compositions and methods related to mrna translational enhancer elements
|
AU2009210266B2
(en)
|
2008-01-31 |
2015-01-29 |
CureVac SE |
Nucleic acids comprising formula (NuGlXmGmGnNv)a and derivatives thereof as an immunostimulating agents/adjuvants
|
DE102008009199A1
(en)
*
|
2008-02-15 |
2009-08-27 |
Forschungszentrum Karlsruhe Gmbh |
Reaction mixer system for mixing and chemical reaction of at least two fluids
|
WO2009127230A1
(en)
|
2008-04-16 |
2009-10-22 |
Curevac Gmbh |
MODIFIED (m)RNA FOR SUPPRESSING OR AVOIDING AN IMMUNOSTIMULATORY RESPONSE AND IMMUNOSUPPRESSIVE COMPOSITION
|
JP4798174B2
(en)
*
|
2008-05-21 |
2011-10-19 |
株式会社日立プラントテクノロジー |
Emulsifying device
|
PL215513B1
(en)
|
2008-06-06 |
2013-12-31 |
Univ Warszawski |
New borane phosphate analogs of dinucleotides, their application, RNA particle, method of obtaining RNA and method of obtaining peptides or protein
|
WO2010037408A1
(en)
|
2008-09-30 |
2010-04-08 |
Curevac Gmbh |
Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
|
WO2010088927A1
(en)
|
2009-02-09 |
2010-08-12 |
Curevac Gmbh |
Use of pei for the improvement of endosomal release and expression of transfected nucleic acids, complexed with cationic or polycationic compounds
|
HUE056773T2
(en)
|
2009-06-10 |
2022-03-28 |
Arbutus Biopharma Corp |
Improved lipid formulation
|
EP2281579A1
(en)
|
2009-08-05 |
2011-02-09 |
BioNTech AG |
Vaccine composition comprising 5'-Cap modified RNA
|
US20110053829A1
(en)
|
2009-09-03 |
2011-03-03 |
Curevac Gmbh |
Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
|
KR101148080B1
(en)
*
|
2009-12-07 |
2012-06-13 |
(주)인사이드밸류 |
Apparatus for mixing fluids
|
WO2011069529A1
(en)
|
2009-12-09 |
2011-06-16 |
Curevac Gmbh |
Mannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
|
WO2011127255A1
(en)
*
|
2010-04-08 |
2011-10-13 |
Merck Sharp & Dohme Corp. |
Preparation of lipid nanoparticles
|
EP2387999A1
(en)
|
2010-05-21 |
2011-11-23 |
CureVac GmbH |
Histidine-containing solution for transfection and/or injection of nucleic acids and uses thereof
|
WO2012009644A2
(en)
|
2010-07-16 |
2012-01-19 |
Arizona Board Of Regents |
Methods to identify synthetic and natural rna elements that enhance protein translation
|
DK2449113T3
(en)
|
2010-07-30 |
2016-01-11 |
Curevac Ag |
Complex formation of nucleic acids with the disulfide cross-linked cationic components for transfection and immunostimulation
|
WO2012019630A1
(en)
|
2010-08-13 |
2012-02-16 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
|
WO2012089225A1
(en)
|
2010-12-29 |
2012-07-05 |
Curevac Gmbh |
Combination of vaccination and inhibition of mhc class i restricted antigen presentation
|
EP3202760B1
(en)
|
2011-01-11 |
2019-08-21 |
Alnylam Pharmaceuticals, Inc. |
Pegylated lipids and their use for drug delivery
|
WO2012116715A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in newborns and infants
|
WO2012113413A1
(en)
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
WO2012116714A1
(en)
|
2011-03-02 |
2012-09-07 |
Curevac Gmbh |
Vaccination in elderly patients
|
WO2013103659A1
(en)
|
2012-01-04 |
2013-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus
|
EP2623121A1
(en)
|
2012-01-31 |
2013-08-07 |
Bayer Innovation GmbH |
Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
|
WO2013113325A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Negatively charged nucleic acid comprising complexes for immunostimulation
|
WO2013113326A1
(en)
|
2012-01-31 |
2013-08-08 |
Curevac Gmbh |
Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
|
WO2013120499A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
|
WO2013120498A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
|
WO2013120497A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
|
WO2013120500A1
(en)
|
2012-02-15 |
2013-08-22 |
Curevac Gmbh |
Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
|
JP6301906B2
(en)
|
2012-03-27 |
2018-03-28 |
キュアバック アーゲー |
Artificial nucleic acid molecule containing 5 'TOPUTR
|
CN104220599A
(en)
|
2012-03-27 |
2014-12-17 |
库瑞瓦格有限责任公司 |
Artificial nucleic acid molecules
|
CA2859452C
(en)
|
2012-03-27 |
2021-12-21 |
Curevac Gmbh |
Artificial nucleic acid molecules for improved protein or peptide expression
|
WO2013174409A1
(en)
|
2012-05-25 |
2013-11-28 |
Curevac Gmbh |
Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings
|
SG11201506052PA
(en)
|
2013-02-22 |
2015-09-29 |
Curevac Gmbh |
Combination of vaccination and inhibition of the pd-1 pathway
|
WO2015002667A1
(en)
|
2013-07-01 |
2015-01-08 |
Myq, Inc. |
A location regulated point-of-sale system and enhancements
|
WO2015024668A2
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Respiratory syncytial virus (rsv) vaccine
|
RU2733424C2
(en)
|
2013-08-21 |
2020-10-01 |
Куревак Аг |
Method for increasing the expression of encoded rna proteins
|
CN105517566A
(en)
|
2013-08-21 |
2016-04-20 |
库瑞瓦格股份公司 |
Composition and vaccine for treating prostate cancer
|
WO2015024665A1
(en)
|
2013-08-21 |
2015-02-26 |
Curevac Gmbh |
Rabies vaccine
|
KR20160042935A
(en)
|
2013-08-21 |
2016-04-20 |
큐어백 아게 |
Composition and Vaccine for Treating Lung Cancer
|
CA2915730A1
(en)
|
2013-08-21 |
2015-02-26 |
Karl-Josef Kallen |
A combination rsv/influenza a vaccine
|
ES2806575T3
(en)
|
2013-11-01 |
2021-02-18 |
Curevac Ag |
Modified RNA with decreased immunostimulatory properties
|
US9956532B2
(en)
*
|
2013-11-07 |
2018-05-01 |
U.S. Department Of Energy |
Apparatus and method for generating swirling flow
|
CN111304231A
(en)
|
2013-12-30 |
2020-06-19 |
库瑞瓦格股份公司 |
Artificial nucleic acid molecules
|
WO2015101416A1
(en)
|
2013-12-30 |
2015-07-09 |
Curevac Gmbh |
Methods for rna analysis
|
CA2927254C
(en)
|
2013-12-30 |
2023-10-24 |
Curevac Ag |
Artificial nucleic acid molecules
|
EP3110401A4
(en)
|
2014-02-25 |
2017-10-25 |
Merck Sharp & Dohme Corp. |
Lipid nanoparticle vaccine adjuvants and antigen delivery systems
|
JP6373749B2
(en)
*
|
2014-12-19 |
2018-08-15 |
富士フイルム株式会社 |
Liposome production method and liposome production apparatus
|
US10035113B2
(en)
*
|
2015-02-26 |
2018-07-31 |
Tokyo Electron Limited |
Method and system for a spiral mixer
|
EP3288671A4
(en)
|
2015-04-28 |
2019-01-16 |
The University Of British Columbia |
Disposable microfluidic cartridge
|
JP6925020B2
(en)
|
2017-03-22 |
2021-08-25 |
国立大学法人横浜国立大学 |
Mixing device and mixing method
|